This may be attributed to tumor heterogeneity, and HER2‐positive cancer cells can be eliminated by targeted therapy whereas HER2‐negative cancer cells cannot be eliminated owing to their insensitivity to targeted therapy. The gene discussed is ERBB2; the disease is cancer.